AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients

Leeford Healthcare bets Rs. 200 crore on orthopedic & mobility aids

Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign

GSK strikes deal with US to lower prescription drug costs & boost respiratory medicine access

GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%

Replacing confusion with clarity: Global Cancer Care launches Mumbai ops to tackle detection delays

The initiative is focused on a problem that continues to plague cancer outcomes in India

Merck strikes historic deal with Trump admin to lower drug costs for Americans

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million